Skip to content
Menu

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Benzinga Newsdesk 8 months ago

NewsPrice TargetAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.

Read at benzinga.com